A. C. Palmer

An RNA Damage Response Network Mediates the Lethality of 5-FU in Clinically Relevant Tumor Types

This paper shows 5-FU's lethality in tumors is due to an RNA damage response, not DNA damage, and that targeting this response could improve cancer therapy.

Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism

The paper shows that concurrent chemotherapy maximizes tumor cell kill despite drug antagonism due to an ultrasensitive dose response.

Crosslinker Structure Modulates Bulk Mechanical Properties and Dictates hMSC Behavior on Hyaluronic Acid Hydrogels

This paper shows that the structure of peptoid crosslinkers affects hydrogel stiffness and influences hMSC behavior, with stiffer crosslinkers increasing modulus and modulating cell morphology and IDO production.

Cancer patient survival can be accurately parameterized, revealing time-dependent therapeutic effects and doubling the precision of small trials

The paper imputes survival data from oncology trials and shows that using Weibull distributions improves trial precision and reveals time-dependent therapeutic effects in immune checkpoint inhibitor trials.

Mechanisms of antibiotic action shape the fitness landscapes of resistance mutations

This study models how antibiotic mechanisms affect resistance mutation fitness, finding that drug type has little impact on resistance selection but that heterogeneous binding enables secondary mutations under certain conditions.

Comparing the efficacy of cancer therapies between subgroups in basket trials

This paper uses permutation testing to compare cancer therapy efficacy across subgroups in basket trials, identifying missed therapeutic benefits in specific mutations.

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts

This study identifies biomarker-guided treatment strategies for ovarian cancer using patient-derived tumor xenografts, finding that nearly 90% of PDXs responded to at least one targeted therapy.

A curative combination therapy for lymphomas achieves high fractional cell killing through low cross-resistance and drug additivity but not synergy

This study analyzes the R-CHOP combination therapy for lymphomas, finding low cross-resistance and drug additivity rather than synergy contribute to its effectiveness.

Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming